symposium on tumour heterogeneity · 2019-10-17 · transcan-2 presenting the projects from the...

4
ERA-NET: Aligning National/Regional Translational Cancer Research Programmes and Activities - TRANSCAN-2 Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of “Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy” SYMPOSIUM ON TUMOUR HETEROGENEITY Palazzo Pirelli, Milan October 24th 2019

Upload: others

Post on 21-Apr-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: SYMPOSIUM ON TUMOUR HETEROGENEITY · 2019-10-17 · TRANSCAN-2 Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of

ERA-NET: Aligning National/Regional Translational Cancer Research Programmes and Activities - TRANSCAN-2

Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of “Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy”

SYMPOSIUM ONTUMOUR HETEROGENEITY

Palazzo Pirelli, Milan

October 24th

2019

Page 2: SYMPOSIUM ON TUMOUR HETEROGENEITY · 2019-10-17 · TRANSCAN-2 Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of

08:00 Registration

09:00 Welcome address by Marina Gerini, General Director Fondazione Regionale per la Ricerca Biomedica

09:10 Overview of TRANSCAN and JTC2014 (EC co-funded) Silvia Paradisi, National Institute of Health, Italy

Presentations of JTC 2014 projects co-funded by the EC

FIRST SESSIONChair: Ulrich Pfeffer, IRCCS Ospedale Policlinico San Martino, Italy

9:20 Targeting of resistance in pediatric oncology (TORPEDO) Jan Molenaar, Princess Maxima Center, The Netherlands

9:40 Overcoming neuroblastoma tumour heterogeneity, resistance and recurrence (ONTHETRRAC) Peter Ambros, Children’s Cancer Research Institute, Austria

10:00 Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation (ITEM) Massimo Guidoboni, IRCCS IRST, Italy

10:20 Cancer evolution and identification of relapse-initiating cells (CEVIR) Christoph Klein, Ludwig-Maximilians - Universität Munich, Germany

11:40 Coffee break

Program

SECOND SESSION Chair: Atanasio Pandiella, Centro de Investigación del Cáncer, CSIC, Spain

11:10 Fighting resistance in CLL (FIRE-CLL) Eric Eldering, Academic Medical Center Department of Experimental Immunology, Amsterdam, Netherlands

11:30 Genetic and cellular intratumour heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance (GCH-CLL) Olivier Bernard, Institut Gustave Roussy, France

11:50 Defeating recurrence and resistance in AML: Multigenomic approaches to analyse heterogeneity (DRAMA) Saverio Minucci, Istituto Europeo di Oncologia, Milan, Italy

12:10 Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy (IntraMMclo) Jana Jakubikova, Cancer Research Institute SAS, Slovakia

12:30 Lunch

Page 3: SYMPOSIUM ON TUMOUR HETEROGENEITY · 2019-10-17 · TRANSCAN-2 Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of

THIRD SESSIONChair: Peter Devilee, Leiden University, The Netherlands

13:30 Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial (ARREST) Liam McDonnell, Fondazione Pisana per la Scienza ONLUS, Pisa, Italy

13:50 Targeting colon tumour initiating cell heterogeneity (TACTIC) Jan Paul Medema, Academic Medical Center/LEXOR, University of Amsterdam, The Netherlands

14:10 Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and epigenetic study of intraTumoural heterogeneity dynamics (INTRACOLOR) Héctor G. Palmer, VHIO, Barcelona, Spain

14:30 Patient-derived models for intratumour functional heterogeneity and its implications for personalized medicine (BeFIT) Huei-Wen Chen, National Taiwan University, Taipei

14:50 Poster session

FOURTH SESSION Chair: Rolf Skotheim, Oslo University Hospital, Norway

16:20 Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer (HetMet) Stian Knappskog, University of Bergen, Norway

16:40 Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response (TH4RESPONS) Manfred Dietel, Institute of Pathology, Charité University Hospital Berlin, Germany

17:00 Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance (PROMETOV) Christiane A. Opitz, German Cancer Research Center, Germany

17:20 Discussion: The impact and added value of transnational collaborations on cancer research Chairs: Hubert Misslisch, DLR, Germany and Jennifer Barrett, University of Leeds, UK

18:20/20:00

Networking dinner and poster prize ceremony

Page 4: SYMPOSIUM ON TUMOUR HETEROGENEITY · 2019-10-17 · TRANSCAN-2 Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of

Organizing committee: Dr. Liron Even-Faitelson, Chief Scientist Office, Israeli Ministry of Health, [email protected]

Dr. Eva Batista, Ministry of Education, Science and Sport, Slovenia, [email protected]

Dr. Silvia Paradisi, National Institute of Health, Italy

Ms. Chiara Consonni, Fondazione Regionale per la Ricerca Biomedica, Italy

Ms. Carmen De Francesco, Fondazione Regionale per la Ricerca Biomedica, Italy

Ms. Maria Romero, Ministry of Health, Italy

The event is hosted by Regione Lombardia with the collaboration of Fondazione Regionale per la Ricerca Biomedica

PARTICIPATION IS FREE OF CHARGE Please register online by October 3rd: https://forms.gle/Dg4knLwNLeU66kJe8)

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 643638